BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 17401430)

  • 1. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 gain of function: the NF-Y connection.
    Peart MJ; Prives C
    Cancer Cell; 2006 Sep; 10(3):173-4. PubMed ID: 16959607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutations: gains or losses?
    Michalovitz D; Halevy O; Oren M
    J Cell Biochem; 1991 Jan; 45(1):22-9. PubMed ID: 2005181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [P53 and cancers].
    May P; May E
    Pathol Biol (Paris); 1995 Mar; 43(3):165-73. PubMed ID: 7675543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dominant negative activity of mutated p53 proteins].
    Dridi W; Krabchi K; Gadji M; Lavoie J; Bronsard M; Fetni R; Drouin R
    Med Sci (Paris); 2006 Mar; 22(3):301-7. PubMed ID: 16527213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
    Roemer K
    Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discerning the function of p53 by examining its molecular interactions.
    Oliner JD
    Bioessays; 1993 Nov; 15(11):703-7. PubMed ID: 8292000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
    Adhikari AS; Iwakuma T
    Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
    Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
    Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 proteins: between loss and gain of function.
    Strano S; Dell'Orso S; Mongiovi AM; Monti O; Lapi E; Di Agostino S; Fontemaggi G; Blandino G
    Head Neck; 2007 May; 29(5):488-96. PubMed ID: 17123310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.